BLFE: AI 评分 48/100 — AI 分析 (4月 2026)

BioLife Sciences Inc. develops and distributes antibacterial products and non-contact human temperature screening technology. The company offers disinfecting wipes, UV sterilization technology, and antimicrobial textiles.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

BioLife Sciences Inc., operating in the healthcare sector, develops and distributes antibacterial and temperature screening products. The company focuses on disinfecting wipes, UV sterilization, electrostatic disinfection, and antimicrobial textiles. It caters to a market seeking enhanced hygiene and safety solutions, particularly in the wake of increased health awareness.

BLFE是做什么的？

BioLife Sciences Inc., incorporated in 2018 and based in Mississauga, Canada, operates within the medical instruments and supplies industry. The company specializes in developing, licensing, and distributing a range of antibacterial products and non-contact human temperature screening technology. Its product portfolio includes disinfecting wipes designed for surface sanitation, UV sterilization technology aimed at eliminating pathogens, electrostatic disinfection services for comprehensive area cleaning, and anti-microbial textiles intended to inhibit bacterial growth on fabrics. Additionally, BioLife Sciences offers touchless vending and marketplace products, catering to the growing demand for contactless solutions in retail and public spaces. The company's focus is on providing solutions that promote hygiene and safety across various environments. BioLife Sciences aims to capitalize on the increasing awareness and demand for infection control measures, positioning itself as a provider of innovative and effective hygiene solutions.

BLFE的投资论点是什么？

BioLife Sciences Inc. operates in the growing hygiene and infection control market. The company's focus on antibacterial products and temperature screening technology aligns with current health and safety concerns. However, negative profit and gross margins of -308.0% and -239.3% respectively, coupled with a negative P/E ratio, indicate financial challenges. The company's small size, with only 3 employees, and OTC listing introduce additional risks. Potential investors should carefully consider the company's financial performance and market position before investing. Growth catalysts include expanding product lines and market reach, but these must be balanced against the financial risks.

BLFE在哪个行业运营？

BioLife Sciences Inc. operates in the medical instruments and supplies industry, which has seen increased demand for hygiene and infection control products. The market is competitive, with companies like BIOAF, BNYN, EMYSF, NVNO, and PHRX offering similar products. The industry is driven by increasing health awareness and stringent regulations. BioLife Sciences focuses on antibacterial products and temperature screening, aligning with current market trends. However, it faces competition from larger, more established players with greater resources and market reach.

Medical - Instruments & Supplies

Healthcare

BLFE有哪些增长机遇？

Expansion of Product Line: BioLife Sciences can expand its product line to include more specialized disinfection solutions, such as hospital-grade disinfectants or advanced air purification systems. The global disinfection market is projected to reach $10.9 billion by 2027, offering a significant opportunity for growth. Timeline: 1-2 years.
Geographic Expansion: The company can expand its geographic reach beyond Canada to target new markets in the United States and Europe. The increasing awareness of hygiene and infection control in these regions presents a favorable environment for growth. Timeline: 2-3 years.
Strategic Partnerships: BioLife Sciences can form strategic partnerships with healthcare providers, schools, and businesses to integrate its products into their operations. These partnerships can provide a steady stream of revenue and increase brand awareness. Timeline: Ongoing.
Development of Innovative Technologies: Investing in research and development to create innovative technologies, such as self-disinfecting surfaces or advanced temperature screening systems, can differentiate BioLife Sciences from its competitors and attract new customers. Timeline: 3-5 years.
Focus on Antimicrobial Textiles: The antimicrobial textiles market is growing due to increasing demand for infection control in healthcare and other industries. BioLife Sciences can focus on developing and marketing antimicrobial textiles for various applications, such as medical apparel and bedding. Timeline: 2-3 years.

Market Cap of $0.00B reflects the company's small size and early stage.
Negative P/E ratio indicates the company is not currently profitable.
Profit Margin of -308.0% highlights significant financial losses.
Gross Margin of -239.3% suggests challenges in product pricing and cost management.
Beta of -2290.12 indicates high volatility and a negative correlation with the market.

BLFE提供哪些产品和服务？

Develops antibacterial products
Licenses antibacterial technologies
Distributes antibacterial products
Develops non-contact human temperature screening technology
Offers disinfecting wipes
Provides UV sterilization technology
Offers electrostatic disinfection services
Provides anti-microbial textiles

BLFE如何赚钱？

Develops and patents antibacterial technologies
Licenses its technologies to other companies
Manufactures and sells antibacterial products
Provides disinfection services

Hospitals and healthcare facilities
Schools and educational institutions
Businesses and offices
Retail stores and supermarkets
Government agencies

Proprietary antibacterial technologies
Established distribution network
Strong relationships with key customers
Focus on innovation and product development

什么因素可能推动BLFE股价上涨？

Upcoming: Potential new partnerships to expand distribution channels.
Ongoing: Increasing demand for hygiene products due to heightened health awareness.
Ongoing: Development of new and innovative disinfection technologies.

BLFE的主要风险是什么？

Potential: Intense competition from larger companies with greater resources.
Potential: Fluctuations in raw material prices affecting profit margins.
Potential: Changes in regulations and standards impacting product compliance.
Ongoing: Negative profit and gross margins indicating financial instability.
Ongoing: OTC listing indicating higher risk and lower liquidity.

BLFE的核心优势是什么？

Focus on high-demand hygiene products
Diverse product portfolio
Potential for innovation in disinfection technologies
Established distribution network

BLFE的劣势是什么？

Small company size and limited resources
Negative profit and gross margins
OTC listing indicates higher risk
Limited brand recognition

BLFE有哪些机遇？

Expansion into new markets
Strategic partnerships with healthcare providers
Development of innovative disinfection solutions
Increased demand for hygiene products due to health concerns

BLFE面临哪些威胁？

Competition from larger, more established companies
Fluctuations in raw material prices
Changes in regulations and standards
Economic downturn affecting demand for hygiene products

BLFE的竞争对手是谁？

BioAdaptives, Inc. — Focuses on adaptogenic and immunomodulatory products. — (BIOAF)
Banyan Acquisition Corporation — Special purpose acquisition company (SPAC). — (BNYN)
Emyria Ltd — Develops cannabinoid-based medicines. — (EMYSF)
Enviro Technologies U.S. Inc. — Focuses on environmental technologies. — (NVNO)
Pherox BioScience, Inc. — Develops and commercializes novel therapeutics. — (PHRX)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Justin De Four
Headquarters: Henderson, CA
Employees: 3
Founded: 2005

AI Insight

AI analysis pending for BLFE

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does BioLife Sciences Inc. do?

BioLife Sciences Inc. specializes in developing, licensing, and distributing antibacterial products and non-contact human temperature screening technology. The company's product line includes disinfecting wipes, UV sterilization technology, electrostatic disinfection services, and anti-microbial textiles. These products cater to various sectors, including healthcare, education, and retail, addressing the increasing demand for hygiene and infection control solutions. The company aims to provide effective and innovative solutions to promote safer and healthier environments.

What do analysts say about BLFE stock?

As of 2026-03-17, there is no available analyst coverage or consensus on BioLife Sciences Inc. (BLFE) stock. The company's small market capitalization and OTC listing may contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as P/E ratio and profit margins, indicate financial challenges that warrant careful consideration.

What are the main risks for BLFE?

BioLife Sciences Inc. faces several risks, including intense competition from larger, more established companies in the hygiene and infection control market. The company's negative profit and gross margins indicate financial instability and challenges in achieving profitability. As an OTC-listed stock, BLFE is subject to higher price volatility and lower liquidity. Changes in regulations and standards related to disinfection products could also impact the company's operations and financial performance. These risks should be carefully considered before investing in BLFE.